Explanation
Epidemiologically, yellow fever is the most likely due to the yearly incidence as compared with Rift Valley HF; so, the most likely answer is “C”. The biphasic presentation of this case also makes YF more likely.
2. FLAVIVIRIDAE
Yellow fever virus was the first human virus to be described (1901) and serves as the type species for the Flaviviridae, which contain several hemorrhagic fever (yellow fever, dengue, Omsk hemorrhagic fever, Kyanasur forest disease, and Alkhurma virus) and encephalitis viruses (Japanese encephalitis, West Nile encephalitis, St. Louis encephalitis, Russian spring-summer encephalitis, and Powassan encephalitis). Flaviviruses are small (50 nm), single-stranded positive-polarity (positive-sense) RNA viruses, and their distributions are restricted by vector and reservoir hosts. The remainder of the discussion on flaviviruses will focus on yellow fever and dengue, as these are by far the two most important diseases caused by this group.
2.1. Yellow fever
2.1.1. Etiology
• Yellow fever virus (YF or YFV):
o Single-stranded positive-polarity (positive-sense) RNA
o Spherical
o Enveloped (sensitive to lipases, organic solvents and detergents)
o 50 nm in diameter
o Two genotypes:
Genotype I: East and central Africa
Genotype II (with two sublineages): Genotype IIA in West Africa and genotype IIB in America
o Vectors: Mostly Aedes spp. mosquitoes
o Reservoir: Primates
2.1.2. Epidemiology
• Outbreaks and epidemics distributed in sub-Saharan Africa, central and South America, as well as the Caribbean
• Two types of transmission cycles: jungle (sylvatic) and urban
o Jungle yellow fever refers to the natural cycle in which the infection is spread from monkey to monkey via the mosquito bite (Aedes africanus, A. furcifer, A. luteocephalus, and other Aedes spp. in Africa, and Haemagogus and Sabethes spp. in the Americas); humans in this case get infected when they encroach this cycle
o Urban yellow fever refers to the human to human spread of the virus via the mosquito (A. aegypti) bite following the introduction of the virus into urban areas by sylvatically-infected individuals; most yellow fever outbreaks and epidemics are caused by the urban cycle
•Primates serve as reservoir hosts
• Yearly incidence of 200 000 infections, with 30 000 deaths
• Case fatality rates for individuals with late stage are variable, but approximate 20% (and as high as 50% during some epidemics)
2.1.3. Incubation period
• 3 to 6 days (can be as long as 14 days)
2.1.4. Duration
• 6 to 10 days (typically) or more
2.1.5. Symptoms and course of disease
• Non-specific febrile illness to life-threatening hemorrhagic fever
• Period of infection (usually lasts 3 days, can last up to several days): Viremic stage during which the patient is infectious and can serve as a source of infection for the vector; it is characterized by an abrupt onset of high fever, chills, malaise, headache, myalgias, lumbosacral pain, dizziness, anorexia, nausea and vomiting, along with congestion of conjunctivae and face, reddening of the tongue edges, Faget’s sign (heart rate does not increase with fever) - Laboratory findings: Leucopenia with relative neutropenia
• Abortive cases: The patient recovers fully with no further signs or symptoms (most common presentation)
•Remission 2 to 24 hours
• Late stage (also referred to as the intoxication period; typically lasts 3 to 5 days): Recurrence of the symptoms with epigastric pain, onset of jaundice, renal dysfunction, oliguria, hypotension, and hemorrhagic diathesis [hematemesis, melena, metrorrhagia, petechiae, ecchymoses, epistaxis, bleeding of the mucous membranes (gums, nose, eyes, rectum)] – Laboratory findings: Increased bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, albuminuria, azotemia, thrombocytopenia, prolonged clotting and prothrombin times, global reduction in clotting factors
• At this stage, the patient can still recover
• Preterminal events: Include hypothermia, delirium, hypoglycemia, hyperkalemia, stupor and coma
• Death usually occurs after 7 to 10 days after the onset of the disease
2.1.6. Diagnosis
• Often clinical (and epidemiologic)
• Laboratory: Mostly RT-PCR and ELISA (4-fold increase in IgM on a single serum sample provides a presumptive diagnosis); paired acute- and convalescent-phase samples provide confirmation; these tests are not commercially available and have to be done by specialized laboratories; older tests include hemagglutination inhibition, complement fixation, neutralization, and indirect immunofluorescence assays
• Epidemiology and research: Virus isolation and culture, and RT-PCR
• Differential diagnoses include: Viral hepatitis (especially hepatitis D, and hepatitis E in pregnant women), leptospirosis, dengue hemorrhagic fever, West Nile hepatitis, Rift Valley fever, Congo-Crimean hemorrhagic fever, severe malaria, Q fever, and typhoid fever; other viral hemorrhagic fevers are usually not associated with jaundice
2.1.7. Pathogenesis
• Virus inoculation through mosquito bite
• Viral replication in draining lymph nodes
• Viral spread to other tissues (liver, spleen, bone marrow, heart, and skeletal muscle) through blood
• Viral infection is directly involved in hepatocellular damage; Kupffer cells are infected first, followed by hepatocytes
• Renal failure (acute tubular necrosis) as a consequence of lower blood volume (shock)
• Direct viral injury to myocytes might contribute to shock, as well as TNF- and nitric oxide produced by infected or activated Kupffer cells and splenic macrophages, through cell injury, oxygen radical production, and microvascular damage
2.1.8. Immunology
• Yellow fever infection recovery provides life-long immunity to yellow fever virus (in the form of neutralizing antibodies)
2.1.9. Complications
• Superimposed bacterial pneumonia and sepsis
2.1.10. Treatment
• Supportive: Treatment is symptomatic with rest, fluid, electrolyte, and acid base management; non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or acetaminophen
• Salycilates are to be avoided
2.1.11. Prevention
• Vaccination: A relatively safe and effective vaccine is available (Yellow fever virus 17D strain), which affords protective immunity (neutralizing antibodies) in 10 (90%) to 30 (99%) days; the vaccine, which is good for 10 years, probably provides life-long immunity and is a legal requirement for entry in certain countries. Severe adverse reactions (neurological and visceral) to the vaccine, although rare, are to be considered prior to undertake attempts to achieve herd immunity
• Vector control, especially of A. aegypti
• Personal protection: Use of long sleeves, insect repellents, and mosquito nets (the vectors are furtive feeders and tend to be diurnal)
• Sensitive to lipases, organic solvents, and detergents